Chelsea Therapeutics to Present at the 25th Annual ROTH Conference
CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25^TH Annual
ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a
corporate update and an overview of the Northera™ (droxidopa) development
Mr. Oliveto's presentation will be webcast live and archived for 30 days on
Chelsea's website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
Fara Berkowitz/Susan Kim
Chelsea Therapeutics Logo
Press spacebar to pause and continue. Press esc to stop.